THE COMBINATION OF CDK4 AND MAPK/ERK PATHWAY INHIBITOR THERAPY IN MELANOMA: DEFINING MELANOMA CELL INTRINSIC AND IMMUNE MEDIATED RESPONSES
Grant number: 1100189 | Funding period: 2016 - 2019
Early-stage melanomas can often be cured with surgery, but more advanced melanomas are harder to treat because standard melanoma treatments do not induce long term disease control. Thus newer types of treatment are required to treat more advanced melanomas. Our proposal will use a drug that stops melanoma cells from growing and in combination with other drugs causes the cells to release factors that activate the immune system to eliminate the tumour.
Related publications (5)
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory
Emily J Lelliott, Isabella Y Kong, Magnus Zethoven, Kelly M Ramsbottom, Luciano G Martelotto, Deborah Meyran, Joe Jiang Zhu, Matteo Costacurta, Laura Kirby, Jarrod J Sandow, Lydia Lim, Pilar M Dominguez, Izabela Todorovski, Nicole M Haynes, Paul A Beavis, Paul J Neeson, Edwin D Hawkins, Grant A McArthur, Ian A Parish, Ricky W Johnstone
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor-positive brea..
Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
Emily J Lelliott, Stefano Mangiola, Kelly M Ramsbottom, Magnus Zethoven, Lydia Lim, Peter KH Lau, Amanda J Oliver, Luciano G Martelotto, Laura Kirby, Claire Martin, Riyaben P Patel, Alison Slater, Carleen Cullinane, Anthony T Papenfuss, Nicole M Haynes, Grant A McArthur, Jane Oliaro, Karen E Sheppard
Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring..
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
Emily J Lelliott, Carleen Cullinane, Claire A Martin, Rachael Walker, Kelly M Ramsbottom, Fernando Souza-Fonseca-Guimaraes, Shatha Abuhammad, Jessica Michie, Laura Kirby, Richard J Young, Alison Slater, Peter Lau, Katrina Meeth, Jane Oliaro, Nicole Haynes, Grant A McArthur, Karen E Sheppard
Both targeted therapy and immunotherapy have been used successfully to treat melanoma, but the development of resistance and poor ..
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
Claire A Martin, Carleen Cullinane, Laura Kirby, Shatha Abuhammad, Emily J Lelliott, Kelly Waldeck, Richard J Young, Natalie Brajanovski, Donald P Cameron, Rachael Walker, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Richard B Pearson, Rodney J Hicks, Grant A McArthur, Karen E Sheppard
Increased CDK4 activity occurs in the majority of melanomas and CDK4/6 inhibitors in combination with BRAF and MEK inhibitors are ..